Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst
admin 21st September 2017 Uncategorised 0The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. Almost $5 billion bright in 2018, if one analyst’s predictions come true.
More: Pfizer's fast-growing Ibrance romps toward an early B payoff: analyst
Source: fierce